Citations

Clear

1078 citation(s) found for "Gupta, S".

Systematic Review Supporting the American Society of Hematology Practice Guidelines on the Management of Myelofibrosis
Hasan, Bashar , Fleti, Farah , Taki Aldin, Sameh , Moustafa, Amr , Tabiim, Anthony J, Chaaban, Mohammad Karam , Tremblay, Douglas , Vannucchi, Alessandro M , Abdallah, Maya M , Gupta, Vikas , Srisuwananukorn, Andrew , Murad, M Hassan

Mayo Clinic

Blood Advances | November 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026021619 | PMID 43063918 Get It

Myelofibrosis (MF) is a Philadelphia-negative clonal disorder of hematopoietic stem cells associated with substantial clinical practice variation. The American Society of Hematology (ASH) convened a guideline panel that prioritized ten clinical questions to inform evidence-based recommendations. We performed a comprehensive systematic review of MEDLINE, EMBASE, Cochrane databases, and Scopus through January 2025 to identify studies that addressed the ten clinical questions. Meta-analyses were performed where feasible. Two reviewers independently selected and appraised studies. Certainty of evidence was assessed using GRADE. Of 3,007 records screened, 43 unique studies met inclusion criteria for the ten questions. Extended molecular testing identified high-risk mutations (ASXL1, EZH2, SRSF2, IDH1/2) that were significantly associated with decreased overall survival (hazard ratios ranging 1.5-4.5). JAK inhibitors improved spleen and symptom responses in symptomatic lower-risk MF and in patients with anemia, with momelotinib improving transfusion independence. However, survival effects were not clearly demonstrated and hematologic toxicity remained common. Evidence for treating asymptomatic high-risk patients with JAK inhibitors was particularly limited. Early allogeneic hematopoietic cell transplantation was associated with higher early mortality but improved long-term survival compared with delayed transplantation. Pretransplant JAK inhibitor exposure did not significantly affect mortality, GVHD, or graft failure. Evidence for interferon, aspirin, and iron chelation was limited and largely indirect. The certainty of evidence was very low or low across nearly all outcomes.
Comparative survival and time toxicity outcomes of CAR-T versus bispecific antibody therapies in relapsed/refractory FL
Ahmed, Nausheen , Nogueira Serodio, Alline , Villasboas, Jose Caetano , Sharp, John , Voorhees, Timothy J , Houshyar, Samin , Wallace, Danielle S , Wagner, Charlotte , Bock, Allison M , Brooks, Taylor R , Al Any, Haya, Rajab, Mohamed , Gupta, Supriya , Karmali, Reem , Trotier, Daniel C , Pophali, Priyanka , Ricker, Edd , Cherng, Hua-Jay J , Torka, Pallawi , Trabolsi, Asaad , Schatz, Jonathan H , Gupta, Arjun

Mayo Clinic

Blood Advances | October 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020899 | PMID 42962270 Get It

Chimeric antigen receptor T-cell (CAR-T) and CD20xCD3 bispecific antibody (BsAb) therapies are both effective for relapsed/refractory (R/R) follicular lymphoma (FL), but comparative real-world survival outcomes and time toxicity have not been characterized. We performed a multicenter retrospective study of 228 patients with R/R FL treated with standard-of-care CAR-T (n = 141) or BsAb (n = 87) across 17 U.S. academic centers in the third-line or later setting. Progression-free survival (PFS) and overall survival (OS) were stratified by 2 or ≥3 prior lines of therapy (LOT2 or LOT3+), including propensity matching. Time toxicity was measured by physical health care contact days. Median PFS was not reached (NR) with CAR-T and 581 days with BsAb in the LOT2 cohort (p < .0001), and was NR with CAR-T and 584 days with BsAb in the LOT3+ cohort (p = .0064). CAR-T recipients were younger (p < .0001) and had better performance status (p = .007) but were more refractory to prior LOT (p = .017). PFS advantages of CAR-T were independent of these differences. OS did not differ between treatment groups. CAR-T had significantly greater time toxicity over the first year, with higher mean contact days than BsAb in both the LOT2 (58 vs 44) and LOT3+ (69 vs 49) cohorts. In this large multicenter cohort of patients with R/R FL, CAR-T was associated with superior PFS but greater time toxicity compared with BsAb therapy. These findings provide real-world outcomes data and time toxicity benchmarks to support treatment sequencing decision-making in R/R FL.
State-of-the-Art Imaging Biomarkers in Screening of Atherosclerotic Cardiovascular Disease
Sorin, Vera , Fatade, Kemi, Morris, Michael F. , Gupta, Amit , Rajiah, Prabhakar

Mayo Clinic

RadioGraphics | September 24, 2026 | Volume: 46 | Issue: 10 | Pages: No page available

10.1148/rg.260068 | PMID 42784472 Get It

Imaging biomarkers complement traditional risk assessment by enabling direct patient-specific detection and characterization of subclinical atherosclerotic cardiovascular disease, which supports earlier diagnosis, improved risk stratification, and more personalized cardiovascular prevention.
The Role of EVs in the Aging Hematopoietic System
Kosebent, Esra G. , Havranek, Nathalie , Kollmann, Karoline , Kirschner, Kristina , Doma, Eszter , Gupta, Kavya , Kirschner, Kristina

Mayo Clinic

Aging Cell | September 24, 2026 | Volume: 25 | Issue: 10 | Pages: No page available

10.1111/acel.70715 | PMID 42779005 Get It

ABSTRACT Extracellular vesicles (EVs) are membrane‐enclosed nanoparticles that mediate intercellular communication by transferring proteins, nucleic acids, and lipids. Within the hematopoietic system, EVs orchestrate critical signaling between bone marrow (BM) niche cells and hematopoietic stem and progenitor cells (HSPCs) to regulate quiescence, proliferation, and lineage commitment. During aging, senescence and telomere attrition drive a profound remodeling of EV biogenesis and cargo. Aged EVs, particularly those released from senescent mesenchymal stromal cells (MSCs) and osteoblasts, exhibit altered microRNA profiles and reduced protective antioxidants. These changes perpetuate niche dysfunction, induce senescence in recipient cells, and promote myeloid‐biased hematopoiesis. Importantly, this communication is a selective process governed by vesicle‐intrinsic surface signatures, such as tetraspanins and integrins, which interact with specific receptors on distinct hematopoietic subsets to regulate signaling fidelity. Conversely, EVs from young or pluripotent stem cells deliver rejuvenating signals that can restore aged HSPC function and attenuate inflammaging. Elucidating these mechanisms of selective targeting and stress‐responsive cargo remodeling provides vital insights for developing EV‐based diagnostic tools and rejuvenation strategies to prevent age‐related immune imbalances and hematologic malignancies.
Complications of ReActiv8 for chronic low back pain: an analysis of the FDA MAUDE database
Conic, Rosalynn R. Z., Kivanc, Tugba, Fischer, Azadeh, Pasya, Sai K., Palmer, Scott, Kubrova, Eva , Eldrige, Jason S. , Hurdle, Mark FB , Hunt, Christine L., Gupta, Sahil, Kanahan Osman, Sharima, Conic, Rosalynn R.Z. , Kivanc, Tugba Yavuz, Fischer, Azadeh, Pasya, Sai Kumar Reddy , Kanahan-Osman, Sharima , Wang, Daniel , Hunt, Christine L., Gupta, Sahil

Mayo Clinic

Pain Management | September 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-7

10.1080/17581869.2026.2736037 | PMID 42762487 Get It

Acute Moderate Intensity Aerobic Exercise Increases Breast Milk Exosome Concentration In Healthy Lactating Women
Gupta, Devanshi, Klaus, Katherine A. , Sevits, Kyle J., Heppelmann, Carrie J., Kim, Yohan, Szymanski, Linda M. , Lucien, Fabrice, Pataky, Leanne, Heppelmann, Carrie J. , Kim, Yohan, Lucien, Fabrice , Pataky, Mark W

Mayo Clinic

Medicine & Science in Sports & Exercise | September 18, 2026 | Volume: 58 | Issue: 10S | Pages: No page available

10.1249/01.mss.0001263472.97615.d4 Get It

PDS0101 With Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Weiss, J., Chintakuntlawar, Ashish, Worden, Francis P., Mehra, Ranee , Kang, Hyunseok , Zinner, Ralph G., Arnold, Susanne M. , Bhateja, Priyanka, Harrington, Kevin, Gupta, Shilpi, Zhao, Yujie, Pham, Dahn C., Najeeb, Sidra, Kaur, Varinder, Sukari, Ammar, Giri, Anshu , Panella, Timothy J., Grewal, Jaspreet, Galligan, Barbara, Nadler, Eric, Grant, Cliona, Arteta-Bulos, Rafael, Schaaf, David, Price, Katharine A., Kang, Hyunseok , Weiss, Jared, Kaczmar, John M. , Zinner, Ralph , Harrington, Kevin J. , Kaur, Varinder , Sukari, Ammar , Panella, Timothy, Grewal, Jaspreet Singh , Galligan, Barbara Marie, Nadler, Eric , Noble, David J. , Schaaf, David

Mayo Clinic

JAMA Oncology | September 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaoncol.2026.3492 | PMID 42752531 Get It

Importance The incidence of human papillomavirus type 16 (HPV16–positive) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) is rising. Approved therapies offer a durable response to a minority of patients. Objective To determine the efficacy and safety of a therapeutic HPV16-targeted immunotherapy, PDS0101, in combination with pembrolizumab in participants with HPV16-positive R/M HNSCC, with separate evaluation of immune checkpoint inhibitor (ICI)–naive and ICI-resistant cohorts. Design, Setting, and Participants VERSATILE-002 was a phase 2, open-label, multicenter nonrandomized clinical trial conducted at 26 oncology centers from March 29, 2021, to May 15, 2025, across the US, UK, and Ireland using the Simon 2-stage optimal design. Efficacy analyses were performed on modified intent-to-treat (mITT) population; safety analyses included all participants who received 1 or more doses. Eighty-eight participants with histologically confirmed R/M HPV16-positive HNSCC were enrolled, of whom 87 (98.9%) received treatment and composed the safety population. Seventy five (85.2%) were in the mITT population used for efficacy analyses, of whom 53 (70.7%) were ICI-naive with a programmed cell death ligand 1 combined positive score of 1 or greater and 22 (29.3%) were ICI-resistant. Exposures Pembrolizumab (200 mg, intravenously, every 3 weeks for up to 35 cycles) plus subcutaneous PDS0101 (5 scheduled doses per protocol). Main Outcomes and Measures The primary end point was objective response rate (ORR) per the Response Evaluation Criteria in Solid Tumors , version 1.1, by a masked independent central reviewer. Secondary end points included progression-free survival (PFS), median overall survival (mOS), and safety, with exploratory end points of duration of response, disease control rate, and response rates by programmed cell death ligand 1 status. Results Of the 75 patients in the mITT population, the mean (SD) age was 64.0 (8.3) years; 4 individuals (5%) were female and 71 (95%) were male; and 2 individuals (3%) were Asian, 1 (1%) was Black, 5 (7%) were Hispanic, and 71 (95%) were White. Among 53 ICI-naive participants in the mITT cohort, ORR by the central reviewer was 34.0%, median PFS was 5.3 months (95% CI, 2.10-9.00), and mOS was 39.3 months (95% CI, 23.90 to not evaluable). Among 22 ICI-resistant patients in the mITT cohort, no objective responses were observed and the primary end point (ORR by central reviewer) was not met, but mOS was 14.8 months (95% CI, 8.50-26.00). The treatment was well tolerated, with 13.8% experiencing grade 3 or higher treatment-related adverse events. Conclusions and Relevance The results of this nonrandomized clinical trial suggest that PDS0101 plus pembrolizumab showed antitumor activity in ICI-naive HPV16-positive R/M HNSCC, with favorable safety, response rates, and survival outcomes. The findings support further evaluation in a first-line setting. Trial Registration ClinicalTrials.gov Identifier: NCT04260126
Beyond Binary PTEN Loss: Integrating Genomics, Long-Term Outcomes, and AI-Assisted Digital Pathology to Define Actionable PTEN Deficiency in Prostate Cancer.
Zarka, Jabra, Pessoa, Rodrigo Rodrigues , Gupta, Sounak , Chen, Eric, Greipp, Patricia, Orme, Jacob J., Karnes, R. Jeffrey, Cheville, John C. , Heath, Elisabeth, Zarka, Jabra , Greipp, Patricia T. , Childs, Daniel S. , Orme, Jacob J. , Karnes, R. Jeffrey

Mayo Clinic

International Journal of Cancer Care and Delivery | September 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.53876/001a.129758 Get It

Enterochromaffin cells as a cellular integration hub for cooperative microbial signaling to modulate gut serotonin and motility
Xiao, Yang , Till, Lisa , Gupta, Yash, Mercado‐Perez, Arnaldo , Bhagwate, Aditya V., Bellampalli, Shreya S. , Stark, Alejandro , Sekhon, Prabhjot K., Singh, Vaidhvi , Tienter, Dennis, Thompson, Michael A. , Kossick, Kimberlee , Krueger, Eugene W., Kalari, Krishna R., Hawkins, Kaitlyn R., Edwards, Brian S. , Alcaino, Constanza, Guo, Chun‐Jun , Druliner, Brooke R., Ördög, Tamás , Farrugia, Gianrico , Kashyap, Purna , Louwies, Tijs, Mars, Ruben A T, Mercado-Perez, Arnaldo, Bellampalli, Shreya S , Stark Quiroz, Alejandro , Liu, Rongfang , Thompson, Michael A , Kossick, Kimberlee , Lee, Jeong-Heon , van der Es, Daan , Willett, Julia L E , Wongkrasant, Preedajit , Prakash, Y S , Ordog, Tamas , Farrugia, Gianrico , Beyder, Arthur , Smith-Edwards, Kristen M , Kashyap, Purna C , Louwies, Tijs , Mars, Ruben A. , Gupta, Yash , Bhagwate, Aditya , Sekhon, Prabhjot Kaur , Heitman, Laura H. , Krueger, Eugene W. , Lee, Jeong‐Heon , Alcaino, Constanza , Willett, Julia L. E. , Wongkrasant, Preedajit , Prakash, Y. S. , Druliner, Brooke R. , Beyder, Arthur

Mayo Clinic

Proceedings of the National Academy of Sciences | August 24, 2026 | Volume: 123 | Issue: 35 | Pages: No page available

10.1073/pnas.2533336123 | PMID 42636369 Get It

The intestinal epithelium is exposed to diverse combinations of microbiota-derived compounds; however, the mechanisms by which the host integrates these signals remain poorly defined. Studying two highly abundant microbial metabolites, we identified the purine metabolite hypoxanthine as an effector metabolite that directly drives signaling and the short-chain fatty acid butyrate as a regulatory metabolite that conditions host responsiveness. Specifically, hypoxanthine activates the adenosine A1 receptor–TRPC4 axis in enterochromaffin (EC) cells, triggering calcium influx and serotonin release resulting in accelerated gastrointestinal transit locally and increased platelet activation systemically. In contrast, butyrate epigenetically upregulates specific G protein–coupled receptors and ion channels to enhance response to hypoxanthine and the neurotransmitters norepinephrine and dopamine. These findings define a cooperative signaling framework and highlight the role of EC cells as a distinct epithelial signaling hub that senses and integrates microbial metabolite signals to drive physiological responses. Our findings provide a mechanistic foundation for therapeutic strategies that leverage combinatorial microbial signaling.
Myocardial Inflammation and Necrosis in Juvenile Mice Compared with Adult Mice with Coxsackievirus B3 Myocarditis
Ricci, J.F. , Macomb, Logan P. , Gegoutchadze, Katherine, Davis, Charlotte, Ritter, Kyra G, Tomerlin, Priya, Darakjian, Ashley A. , Farahani, N A Sarbandi, Parrow, Lauren M, Strandes, Max W , Khatib, Sami , ElSaygh, Jude, Price, Jack F. , Gupta, Dipankar , Whelan, Emily R. , Tomerlin, Priya I, Beetler, Danielle J. , Florio, Damian N. Di , Cooper, Leslie T. , Fairweather, DeLisa , Bruno, Katelyn A.

Mayo Clinic

No container title available | August 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.20.746108 Get It

Background: Viral myocarditis presents a significant burden of disease, particularly among children and young adults. However, clinical guidelines and treatment strategies for pediatric patients are derived from those for adult patients due to a lack of pediatric data. Current animal models of viral myocarditis use adult mice, so conclusions from these models cannot necessarily be extrapolated to the pediatric population. We sought to develop a juvenile mouse model of myocarditis to examine differences between these two distinct clinical populations. Methods: Male and female BALB/c 3-4-week-old 'juvenile' and 8-week-old 'adult' mice were infected intraperitoneally with 103 PFU of heart-passaged coxsackievirus B3. Sera was used to evaluate testosterone and estradiol levels. Cardiac histological evaluations included overall inflammation, fibrosis, and specific cell-type infiltration. RNA was extracted from cardiac tissue and evaluated for changes in gene expression of cell-type markers, complement components, and NLRP3 inflammasome components. Results: Juvenile mice exhibited more severe inflammation than adult mice but no sex differences in overall inflammation. Juvenile mice demonstrated increased infiltration of CD11b+ cells, F4/80+ cells, and CD3+ T-cells vs. adults. Inflammasome genes NLRP3 and caspase-1 were significantly increased in juvenile compared with adult myocarditis. Conclusions: This paper is the first to describe a juvenile mouse model of coxsackievirus B3 myocarditis and provides a direct comparison to a translational adult mouse model. Juvenile mice had greater cardiac inflammation than adults. This model replicates clinical populations and provides a valuable tool to study age as a factor in the pathogenesis of myocarditis.